— Know what they know.
Not Investment Advice

HRMY

Harmony Biosciences Holdings, Inc.
1W: -0.9% 1M: -2.1% 3M: -29.0% YTD: -26.2% 1Y: -19.4% 3Y: -37.2% 5Y: -10.8%
$27.59
+0.49 (+1.81%)
After Hours: $27.54 (-0.05, -0.18%)
NASDAQ · Healthcare · Biotechnology · $1.6B · Alpha Radar Strong Sell · Power 44
Smart Money Score
Bullish 75
Insider+$13.6M
Congress
ETF Holdings
Key Statistics
Market Cap$1.6B
52W Range25.52-40.87
Volume535,967
Avg Volume858,091
Beta0.91
Dividend
Analyst Ratings
10 Buy 1 Hold 2 Sell
Consensus Buy
Company Info
CEOJeffrey Dayno
Employees268
SectorHealthcare
IndustryBiotechnology
IPO Date2020-08-19
630 West Germantown Pike
Plymouth Meeting, PA 19462
US
484 539 9800
About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Recent Insider Trades

NameTypeSharesPriceDate
Kapadia Sandip S-Sale 3,746 $37.15 2026-01-26
Kapadia Sandip M-Exempt 4,725 2026-01-25
Kapadia Sandip F-InKind 2,553 $36.82 2026-01-25
Kapadia Sandip M-Exempt 4,725 2026-01-25
Serafin Andrew M-Exempt 2,600 2026-01-25

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms